Contraceptive Pills Market by Product, Age Group (15-24, 25-34, 35-44), Route of Administration, Distribution

List of Tables

[182 Pages Report] The Contraceptive Pills Market size was estimated at USD 19.53 billion in 2023 and expected to reach USD 20.76 billion in 2024, at a CAGR 6.46% to reach USD 30.27 billion by 2030.

Global Contraceptive Pills Market

KEY MARKET STATISTICS
Base Year [2023]	USD 19.53 billion
Estimated Year [2024]	USD 20.76 billion
Forecast Year [2030]	USD 30.27 billion
CAGR (%)	6.46%

Contraceptive pills are oral medications that contain synthetic hormones designed to regulate a woman's menstrual cycle and prevent unintended pregnancy. These pharmaceutical products primarily function by inhibiting ovulation, altering the cervical mucus to restrict sperm passage, and modifying the endometrial lining to minimize implantation of a fertilized egg. The growing awareness about family planning methods among different age groups and cultures has increase the demand for safe and effective contraceptives. However, the presence of alternative contraceptive methods or substandard products in the market limits consumers' utilization of contraceptive pills. Nevertheless, developing new formulations that offer improved efficacy and fewer side effects is expected to create potential opportunities for the contraceptive pills market.

Regional Insights

In the Americas region, the contraceptive pills market is growing owing to widespread awareness campaigns, government support, and technological advancements from manufacturers for new contraceptive pill composition. According to the National Library of Medicine (NLM), Approximately 25% of women in the U.S. aged 15-44 currently use contraception pills as their method of choice. In the European region, public health programs promoting family planning education and affordable prices have gained popularity for the use of contraceptive pills. The Asia Pacific region showcases growth prospects for the market in the face of larger population economies such as China & India, creating demand for affordable contraceptive pills. Further, many emerging & developing countries create an opportunistic landscape for the market through the adoption of family planning education & awareness programs.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Contraceptive Pills Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Contraceptive Pills Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Contraceptive Pills Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Afaxys Pharma, LLC, Amneal Pharmaceuticals, Inc., Apotex Inc., Aurobindo Pharma Limited, Bayer AG, Bionpharma Inc., Cipla Limited, Combe Incorporated, Gedeon Richter PLC, Glenmark Pharmaceuticals Limited, Johnson & Johnson Services, Inc., Julie Product Inc., Lupin Limited, Mankind Pharma Ltd., Mayne Pharma Group Limited, Merck & Co., Inc., Northstar Rx LLC, Perrigo Company plc, Pfizer Inc., Piramal Enterprises Ltd., Sun Pharmaceutical Industries Limited, Syzygy Healthcare Solutions, LLC, Teva Pharmaceuticals, Viatris Inc., and Xiromed, LLC.

Market Segmentation & Coverage

This research report categorizes the Contraceptive Pills Market to forecast the revenues and analyze trends in each of the following sub-markets:

Product
- Combination Pill
- Continuous/Extended Pill
- Progesterone Pill
Age Group
- 15-24
- 25-34
- 35-44
- 45 and Above
Route of Administration
- Oral
- Viginal
Distribution
- Offline
- Online
Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam
- Europe, Middle East & Africa
  - Denmark
  - Egypt
  - Finland
  - France
  - Germany
  - Israel
  - Italy
  - Netherlands
  - Nigeria
  - Norway
  - Poland
  - Qatar
  - Russia
  - Saudi Arabia
  - South Africa
  - Spain
  - Sweden
  - Switzerland
  - Turkey
  - United Arab Emirates
  - United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Contraceptive Pills Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Contraceptive Pills Market?

3. What are the technology trends and regulatory frameworks in the Contraceptive Pills Market?

4. What is the market share of the leading vendors in the Contraceptive Pills Market?

5. Which modes and strategic moves are suitable for entering the Contraceptive Pills Market?

Product Code: MRR-A579C4315A26

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

4.1. Introduction
4.2. Contraceptive Pills Market, by Region

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Increasing use of contraceptive pills to prevent unintended pregnancies
  - 5.1.1.2. Growing prevalence and awareness toward sexually transmitted diseases (STDs)
  - 5.1.1.3. Supportive government initiatives to encourage use of contraceptive pills
- 5.1.2. Restraints
  - 5.1.2.1. Adverse health impacts of contraceptive pills
- 5.1.3. Opportunities
  - 5.1.3.1. Ongoing advancements in contraceptive pill formulations and packaging
  - 5.1.3.2. Availability of contraceptive pills on online channels
- 5.1.4. Challenges
  - 5.1.4.1. Safety and social concerns regarding pill usage and issues with product marketing
5.2. Market Segmentation Analysis
- 5.2.1. Product: Significant adoption of combination pills for family planning
- 5.2.2. Age Group: High usage of contraceptive pills in the age group 15 to 24
- 5.2.3. Distribution: Evolving online distribution channels for contraceptive pills
- 5.2.4. Route of Administration: User preferences for oral contraceptive pills owing to ease of use
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter's Five Forces Analysis
- 5.5.1. Threat of New Entrants
- 5.5.2. Threat of Substitutes
- 5.5.3. Bargaining Power of Customers
- 5.5.4. Bargaining Power of Suppliers
- 5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework

6. Contraceptive Pills Market, by Product

6.1. Introduction
6.2. Combination Pill
6.3. Continuous/Extended Pill
6.4. Progesterone Pill

7. Contraceptive Pills Market, by Age Group

7.1. Introduction
7.2. 15-24
7.3. 25-34
7.4. 35-44
7.5. 45 and Above

8. Contraceptive Pills Market, by Route of Administration

8.1. Introduction
8.2. Oral
8.3. Viginal

9. Contraceptive Pills Market, by Distribution

9.1. Introduction
9.2. Offline
9.3. Online

10. Americas Contraceptive Pills Market

10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States

11. Asia-Pacific Contraceptive Pills Market

11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam

12. Europe, Middle East & Africa Contraceptive Pills Market

12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom

13. Competitive Landscape

13.1. FPNV Positioning Matrix
13.2. Market Share Analysis, By Key Player
13.3. Competitive Scenario Analysis, By Key Player
- 13.3.1. Agreement, Collaboration, & Partnership
  - 13.3.1.1. Richter and Mithra sign supply agreement for production of API for combined oral contraceptive Estelle and Donesta
- 13.3.2. New Product Launch & Enhancement
  - 13.3.2.1. FDA approves first nonprescription daily oral contraceptive
  - 13.3.2.2. Gedeon Richter announces availability of oral contraception Drovelis

14. Competitive Portfolio

14.1. Key Company Profiles
- 14.1.1. AbbVie Inc.
- 14.1.2. Afaxys Pharma, LLC
- 14.1.3. Amneal Pharmaceuticals, Inc.
- 14.1.4. Apotex Inc.
- 14.1.5. Aurobindo Pharma Limited
- 14.1.6. Bayer AG
- 14.1.7. Bionpharma Inc.
- 14.1.8. Cipla Limited
- 14.1.9. Combe Incorporated
- 14.1.10. Gedeon Richter PLC
- 14.1.11. Glenmark Pharmaceuticals Limited
- 14.1.12. Johnson & Johnson Services, Inc.
- 14.1.13. Julie Product Inc.
- 14.1.14. Lupin Limited
- 14.1.15. Mankind Pharma Ltd.
- 14.1.16. Mayne Pharma Group Limited
- 14.1.17. Merck & Co., Inc.
- 14.1.18. Northstar Rx LLC
- 14.1.19. Perrigo Company plc
- 14.1.20. Pfizer Inc.
- 14.1.21. Piramal Enterprises Ltd.
- 14.1.22. Sun Pharmaceutical Industries Limited
- 14.1.23. Syzygy Healthcare Solutions, LLC
- 14.1.24. Teva Pharmaceuticals
- 14.1.25. Viatris Inc.
- 14.1.26. Xiromed, LLC
14.2. Key Product Portfolio

15. Appendix

15.1. Discussion Guide
15.2. License & Pricing